Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; nitrogen - canada: cytosar (cytarabine) is indicated primarily for induction and maintenance of remission in acute leukemia in both adults and children. it has been found useful in the treatment of acute myelocytic leukemia, chronic myelocytic leukemia (blast phase), acute lymphocytic leukemia and erythroleukemia. cytosar may be used alone or in combination with other antineoplastic agents; the best results are obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that included cytosar. cytosar has been used intrathecally in newly diagnosed children with acute lymphocytic leukemia as well as in the treatment of meningeal leukemia. cytosar, in high dose 2-3 g/m2 as an i.v. infusion over 1-3 hours given every 12 hours for 2-6 days with or without additional cancer chemotherapeutic agents, has been shown to be effective in the treatment of poor-risk leukemia, refractory leukemia, and relapsed acute leukemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; nitrogen - canada: cytosar (cytarabine) is indicated primarily for induction and maintenance of remission in acute leukemia in both adults and children. it has been found useful in the treatment of acute myelocytic leukemia, chronic myelocytic leukemia (blast phase), acute lymphocytic leukemia and erythroleukemia. cytosar may be used alone or in combination with other antineoplastic agents; the best results are obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that included cytosar. cytosar has been used intrathecally in newly diagnosed children with acute lymphocytic leukemia as well as in the treatment of meningeal leukemia. cytosar, in high dose 2-3 g/m2 as an i.v. infusion over 1-3 hours given every 12 hours for 2-6 days with or without additional cancer chemotherapeutic agents, has been shown to be effective in the treatment of poor-risk leukemia, refractory leukemia, and relapsed acute leukemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - cytarabine, quantity: 100 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; nitrogen - canada: cytosar (cytarabine) is indicated primarily for induction and maintenance of remission in acute leukemia in both adults and children. it has been found useful in the treatment of acute myelocytic leukemia, chronic myelocytic leukemia (blast phase), acute lymphocytic leukemia and erythroleukemia. cytosar may be used alone or in combination with other antineoplastic agents; the best results are obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa2l2) that included cytosar. cytosar has been used intrathecally in newly diagnosed children with acute lymphocytic leukemia as well as in the treatment of meningeal leukemia. cytosar, in high dose 2-3 g/m2 as an i.v. infusion over 1-3 hours given every 12 hours for 2-6 days with or without additional cancer chemotherapeutic agents, has been shown to be effective in the treatment of poor-risk leukemia, refractory leukemia, and relapsed acute leukemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: glycerol; hydrochloric acid; water for injections - canada idarubicin alone or in combination with other anticancer drugs are used in the treatment of: ? acute non-lymphocytic leukaemia as a first line treatment in adults ? acute lymphocytic leukaemia as a second line in adults and children france zavedos solution for infusion is indicated for the treatment of acute myeloid leukemia. zavedos solution for infusion is indicated for the treatment of acute lymphoblastic leukemia in relapse. germany adults zavedos is indicated for use in combination with other cytostatics (such as cytabarine) for the treatment (remission induction and consolidation) of adult patients with acute myeloid leukaemia (aml, anll) who have not received any previous treatment. children and adolescents zavedos, in combination with cytarabine, is indicated for first-line remission induction treatment of children with blood cancer, called acute myeloid leukaemia (aml), who have not received any previous treatment. netherlands adults acute myeloblastic leukaemia (aml): for remission induction as first line treatment or for remission induction in relapsed or refractory patients. acute lymphoblastic leukaemia (all): second line treatment. children acute myeloblastic leukaemia (aml): for remission induction as first line treatment, in combination with cytarabine. acute lymphoblastic leukaemia (all): second line treatment. switzerland acute myeloid leukaemia in combination with other cytostatics. acute lymphatic leukaemia as reserve medication in combination with other cytostatics.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; glycerol - canada idarubicin alone or in combination with other anticancer drugs are used in the treatment of: ? acute non-lymphocytic leukaemia as a first line in adult patients. ? acute lymphocytic leukaemia as a second line in adults and children. thailand zavedos is indicated for use in acute myelogenous leukaemia (aml) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. chile ? acute non-lymphocytic leukemia (anll); also called acute myelogenous leukemia (aml) in children and adults for remission induction as first-line therapy or for remission induction in relapsed or refractory patients. ? acute lymphocytic leukemia (all) as second-line treatment in adults and children. denmark acute leukaemias. paediatric population zavedos, combined with cytarabine, for first-line therapy in children with acute myeloid leukaemia (aml). france ? acute myeloblastic leukaemia. ? idarubicin, in combination with cytarabine is indicated for first-line remission induction treatment in children with acute myeloid leukaemia (aml) who have not undergone previous treatment. ? acute lymphoblastic leukaemia in relapsed patients. finland adults for remission induction in acute myeloid leukemia as primary therapy, or for remission induction in relapsed or refractory patients. children idarubicin, in combination with cytarabin, is indicated for the first remission induction-line treatment of previously untreated children with acute myeloid leukemia (aml). zavedos solution for injection may be used in combination therapy with other cytotoxic agents. india adults acute myeloid leukemia (aml): for the induction of the remission both as first line therapy and for remission induction in relapsed or refractory patients. acute lymphocytic leukemia (all): second-line treatment. children acute lymphocytic leukaemia (all): second line therapy. iceland acute myelogenous leukemia (aml). paediatric population zavedos, combined with cytarabine, for first-line therapy in children with acute myeloid leukaemia (aml). netherlands adults acute myeloid leukaemia (aml): for remission induction as first line treatment or for remission induction in relapse or refractory patients. acute lymphoblastic leukaemia (all): second line treatment. portugal adults acute non-lymphocytic leukaemia, as a first line treatment for induction of remission, or for induction of remission in patients with relapsed or refractory occurrence of the disease. acute lymphocytic leukaemia, as a second line treatment. children acute non-lymphocytic leukaemia, in combination with cytarabine, as a first line treatment for induction of remission. acute lymphocytic leukaemia, as a second line treatment. united kingdom adults for the treatment of acute myeloid leukaemia (aml), for remission induction in untreated patients or for remission induction in relapsed or refractory patients. for second line treatment of relapsed acute lymphoblastic leukaemia (all). paediatric population for first line treatment of acute myeloid-leukaemia (aml), in combination with cytarabine, for remission induction. for second line treatment of relapsed acute lymphoblastic leukaemia (all). zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. ireland adults for the treatment of acute myeloid leukaemia (aml), for remission induction in untreated patients or for remission induction in relapsed or refractory patients. for second line treatment of relapsed acute lymphoblastic leukaemia (all). paediatric population for first line treatment of acute myeloid-leukaemia (aml), in combination with cytarabine, for remission induction. for second line treatment of relapsed acute lymphoblastic leukaemia (all). zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents poland adults: - acute non-lymphocytic leukemia [anll, also referred to as acute myelogenous leukemia (aml)] for remission induction as first-line therapy or for remission induction in relapsed or refractory patients. - acute lymphocytic leukemia (all) as second line treatment. children: - acute myeloid leukemia (aml) in combination with cytarabine, as first line therapy for remission induction. - acute lymphocytic leukemia (all) as second line treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: sorbitol; water for injections; lactic acid - canada irinotecan (irinotecan hydrochloride trihydrate) is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan is also indicated as a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy. egypt campto is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. campto is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - interferon beta-1b, quantity: 0.25 mg/ml - injection, powder for - excipient ingredients: albumin; mannitol - betaferon is indicated for the treatment of: - ambulatory patients with relapsing-remitting multiple sclerosis (ms) characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. - betaferon is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive multiple sclerosis. - the treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent magnetic resonance imaging (mri) lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded.

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ixekizumab - injection, solution - ixekizumab 80 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - indium (111in) pentetate, quantity: 37 mbq/ml - injection, solution - excipient ingredients: water for injections; pentetic acid; sodium bicarbonate - indications as at 11 jan 05 : radionuclide cisternography.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g) - injection, powder for - excipient ingredients: - amoxil parenteral is intended for use where the patient's condition precludes the administration of the oral form. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia: (bacterial) h. influenzae; e. coli (see microbiology); p.mirabilis; streptococcus; s. pneumoniae; s. faecalis and salmonella typhi. skin and skin structure: staphylococcus, non-penicillinase-producing; streptococcus; e. coli (see microbiology). respiratory, acute and chronic: haemophilus influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. co